In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bigger Deal Values by Splitting Indications: PDL's Experience

Executive Summary

It is one of the odder aspects of biotech life that one of the most important new ways to increase the dealmaking value of products has nothing to do with science or negotiating tactics-but sales auditing. PDL Biopharma's deals with Roche and Biogen Idec revive the notion of splitting indications among partners, a strategy apparently killed by the Amgen/J&J battle over EPO.
Advertisement

Related Content

Drug Delivery Heats Up
Drug Delivery Heats Up
Payback: Making Innovation Count in Uncertain Times
Payback: Making Innovation Count in Uncertain Times
Bayer/Regeneron: Typically Rich, Extra Regional
Bayer/Regeneron: Typically Rich, Extra Regional
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma
Biosimilars: The Time Has Come
Biosimilars: The Time Has Come
Biogenerics Are Happening: Slowly, Product-By-Product

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel